CoChat

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients

Open access
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J.P., Gilberg, F., Cunningham, D. · 2011 · Annals of Oncology

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers.Methods A meta-analysis, based on individual patient data from six randomised non-inferiority trials, was carried out at the request of regulatory authorities to compare the effects of single-agent capecitabine or capecitabine-containing chemotherapy versus matched 5-FU-based regimens in terms of overall survival in patients with stage III colon, metastatic colorectal or advanced gastric cancer.Results Data from a total of 6171 patients with stage III colon cancer (n = 1987), metastatic colorectal cancer (n = 3868) or advanced gastric cancer (n = 316) were included. A total of 3097 patients were treated with capecitabine-containing chemotherapy and 3074 patients with 5-FU-containing chemotherapy. The unadjusted hazard ratio for overall survival for capecitabine-containing chemotherapy versus 5-FU-containing chemotherapy was 0.94 (95% confidence interval 0.89-1.00; P = 0.0489).Conclusions Oral capecitabine is at least equivalent to i.v. 5-FU in terms of overall survival in patients with gastrointestinal cancers. Capecitabine and 5-FU can be used interchangeably in these patient populations.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdr031

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Cited by

See all 101

Metadata

Authors
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D.
Affiliations
  • University of Glasgow (GB)
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Leeds (GB)
  • Hospital Sírio-Libanês (BR)
  • Asan Medical Center (KR)
  • F. Hoffmann-La Roche AG (CH)
  • Royal Marsden Hospital (GB)
Corresponding author
Cassidy, J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2011-12
Volume
22
Issue
12
Pages
2604-2609
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2146874279
Cited by
90
References
17
Citations by year
2026: 3 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 8 · 2012: 8
FWCI
0.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Roche
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
capecitabine, 5-fluorouracil, colorectal cancer, gastric cancer, metastatic colorectal cancer, stage III colon cancer, advanced gastric cancer, oral chemotherapy, overall survival, non-inferiority, individual patient data
MeSH terms
Capecitabine, Antineoplastic Agents, Deoxycytidine, Female, Fluorouracil, Humans, Male, Stomach Neoplasms, Colorectal Neoplasms, Multivariate Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. https://app.cochat.ai/papers/10.1093/annonc/mdr031
The paper
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011). Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology. https://doi.org/10.1093/annonc/mdr031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.